PDCD1 and lung cancer: Our study shows delta‐He as a promising prognostic biomarker for lung cancer patients treated with PD‐1/PD‐L1 inhibitors, highlighting its potential to guide therapeutic decisions and improve patient management in a non‐invasive manner.